Anzeige
Mehr »
Freitag, 14.08.2026 - Börsentäglich über 12.000 News
Die Bohrungen sind fast abgeschlossen. Was jetzt kommt, könnte noch wichtiger sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWA4 | ISIN: GB00BMCLYF79 | Ticker-Symbol: 88Q
Xetra
14.08.26 | 17:35
6,000 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
4BASEBIO PLC Chart 1 Jahr
5-Tage-Chart
4BASEBIO PLC 5-Tage-Chart
RealtimeGeldBriefZeit
5,2007,20019:56
Xetra-Umsätze heute
UhrzeitAktienkursStück

Keine Umsätze verfügbar.

Tagesumsatz Xetra0,000
0,00 %

0

 Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.

Aktuelle News zur Aktie 4BASEBIO PLC

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.07.4basebio Plc - Grant of Options & Director/PDMR Dealing3704basebio Plc - Grant of Options & Director/PDMR Dealing PR Newswire LONDON, United Kingdom, July 22 4basebio PLC ("4basebio"...
► Artikel lesen
08.07.4basebio Plc - Director Appointment5844basebio Plc - Director Appointment PR Newswire LONDON, United Kingdom, July 08 4basebio PLC ("4basebio" or the "Company") ...
► Artikel lesen
30.06.4basebio Plc - Result of AGM & Issue of Options4224basebio Plc - Result of AGM & Issue of Options PR Newswire LONDON, United Kingdom, June 30 4basebio PLC ("4basebio"...
► Artikel lesen
4BASEBIO Aktie jetzt für 0€ handeln
16.06.4basebio Plc - Notice of Investor Presentation4104basebio Plc - Notice of Investor Presentation PR Newswire LONDON, United Kingdom, June 16 4basebio...
► Artikel lesen
15.06.IN BRIEF: 4basebio appoints Jeff Coller to Strategic Advisory Board1
Weiter >>
39 Nachrichten in den letzten 12 Monaten
Das könnte Sie auch interessieren
ZeitAktuelle NachrichtenMedien
14:03EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributionEQS Voting Rights Announcement: Evotec SE Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide...
► Artikel lesen
13:18Outlook Therapeutics, Inc.: Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVAThe only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA...
► Artikel lesen
14:48Silexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateSuccessfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center...
► Artikel lesen
14:36BiomX Subsidiary Zorronet Receives Approximately $300,000 Purchase Order to Build Unified Operational Environment at Defense Technology Test and Evaluation SiteNETANYA, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a company focused on defense, security and critical infrastructure technologies, today...
► Artikel lesen
14:06Replimune Group, Inc.: Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate UpdateTUDRIQEV in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends...
► Artikel lesen